Keytruda improves survival in first-line squamous NSCLC

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab plus chemotherapy met the primary endpoints of improving progression-free survival (PFS) and overall survival (OS) in the Phase III KEYNOTE-407 trial as first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC). The company plans to present the data at the American Society of Clinical Oncology meeting in Chicago.

An sBLA for the humanized IgG4 mAb against PD-1 is under FDA review for the indication...